These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37770370)

  • 41. Detection Rate and Localization of Prostate Cancer Recurrence Using
    Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
    J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic Performance of
    Esen B; Seymen H; Tarim K; Koseoglu E; Bolukbasi Y; Falay O; Selçukbiricik F; Molinas Mandel N; Kordan Y; Demirkol MO; Tilki D; Esen T
    Eur Urol Focus; 2023 Sep; 9(5):832-837. PubMed ID: 37032281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of standard and delayed imaging to improve the detection rate of [
    Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
    Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic accuracy of [
    Mingels C; Bohn KP; Rominger A; Afshar-Oromieh A; Alberts I
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2436-2444. PubMed ID: 35067735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
    Tan N; Bavadian N; Calais J; Oyoyo U; Kim J; Turkbey IB; Mena E; Davenport MS
    J Urol; 2019 Aug; 202(2):231-240. PubMed ID: 30829130
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
    Francolini G; Banini M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Roghi M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L
    Prostate; 2023 Sep; 83(12):1201-1206. PubMed ID: 37290915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High detection rate in [
    Watabe T; Uemura M; Soeda F; Naka S; Ujike T; Hatano K; Sasaki H; Kamiya T; Shimosegawa E; Kato H; Cardinale J; Tateishi U; Nonomura N; Giesel FL
    Ann Nucl Med; 2021 Apr; 35(4):523-528. PubMed ID: 33661475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PET/CT With
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
    Alberts I; Bütikofer L; Rominger A; Afshar-Oromieh A
    PLoS One; 2022; 17(7):e0270269. PubMed ID: 35853017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies.
    Mazrani W; Cook GJR; Bomanji J
    Nucl Med Commun; 2022 Jun; 43(6):631-637. PubMed ID: 35438666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
    Morawitz J; Kirchner J; Lakes J; Bruckmann NM; Mamlins E; Hiester A; Aissa J; Loberg C; Schimmöller L; Arsov C; Antke C; Albers P; Antoch G; Sawicki LM
    Eur J Radiol; 2021 Mar; 136():109556. PubMed ID: 33485127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.
    Bianchi L; Castellucci P; Farolfi A; Droghetti M; Artigas C; Leite J; Corona P; Shagera QA; Moreira R; González C; Queiroz M; de Galiza Barbosa F; Schiavina R; Deandreis D; Fanti S; Ceci F
    Eur Urol Oncol; 2023 Feb; 6(1):41-48. PubMed ID: 34933814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.
    Joshi A; Roberts MJ; Perera M; Williams E; Rhee H; Pryor D; Lehman M; Heathcote P; Wood S; Coucher J; Gustafson S; Miles K; Vela I
    Clin Exp Metastasis; 2020 Aug; 37(4):551-560. PubMed ID: 32519046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Head-to-head comparison of prostate-specific membrane antigen positron emission tomography/computed tomography and multiparametric magnetic resonance imaging in the detection of biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    Jiang Z; Yang T; Xu L
    Clin Radiol; 2024 Jun; 79(6):436-445. PubMed ID: 38582633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of
    Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.